Block & Leviton is looking into Candel Therapeutics for possibly misleading investors about its application readiness.

CADL · Candel Therapeutics

The AI's read

The later filing date leaves Candel waiting longer to submit its drug application. The inquiry raises questions about what investors were told about manufacturing checks and timing. It has not found wrongdoing, but the delay and reported share-price fall make the news unfavorable.